Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEAK: Alogliptin and Pioglitazone Combination in T2DM
NCT02231021Phase 4Completed
- Start
- Sep 2014
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Alogliptin + Pioglitazone, Alogliptin and Pioglitazone (3 arms). Primary endpoint: Change in glycohemoglobin (HbA1c) from baseline at 24 weeks. Started Sep 2014; status: completed.
02
Drugs
alogliptinpioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02231021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02231021.